Interestingly, the authors also demonstrated that the mitochondria-targeted antioxidant MitoQ prevents the development of pancreatic cancer in mice with KRAS mutations, indicating that the oncogenic activity of KRAS requires the generation of mitochondrial ROS. Here, KRAS is linked to pancreatic neoplasm.